Company
Every investor coverage indicates participated in a round Spinifex raised.
Investors whose own portfolio pages list Spinifex, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
The transaction that ended Spinifex's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Novartis International | Acquisition | 29 Jun 2015 | $267m | Startup Daily, AFR Technology |
| Novartis | Acquisition | 2015 | $284m+ | Startup Daily, Brandon Capital portfolio (Wed 1 May 2019), Brandon BioCatalyst portfolio, Brandon Capital portfolio (Wed 1 May 2019) |
Companies Spinifex acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Spinifex. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UniSuper commits $75 million to Uniseed, the research commercialisation fund owned by four universities and CSIRO, its first venture investment; past portfolio sales to Schneider Electric, RTP Co and Novartis are recalled.
Birchal's CSF Yearbook 2021 found Australian equity crowdfunding hit record levels in 2021, with $71 million raised across 89 companies, and recalls Biome Australia becoming the first CSF-backed business to join the ASX.
Also Startup Daily
Brandon Capital's blog reports a first close of $210 million toward its $250 million MRCF 5 biotech fund, with super funds and CSL backing, and recalls past portfolio sales of Spinifex and Fibrotech.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily
Swiss pharmaceutical giant Novartis has agreed to acquire Australian drug developer Spinifex Pharma for $US200 million upfront, with up to $US500 million more in milestone payments.
Also Startup Daily